Arkolith/Insider Trading/VERA/Form 4

Fordyce Marshall

PRESIDENT AND CEO, DirectorVera Therapeutics, Inc. (VERA) · full profile →Form 4 · filed Dec 20, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$754K
Net Open-Market Flow
-$754K
Transactions
14
11 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 19, 2024Option exercise(M)58K$2.90$167K144K
Dec 18, 2024Sell(S)5K$43.52$219K86K
Dec 18, 2024Sell(S)5K$44.03$204K86K
Dec 18, 2024Option exercise(M)2K$2.90$5K88K
Dec 18, 2024Sell(S)2K$43.81$82K86K
Dec 18, 2024Option exercise(M)5K$2.90$13K91K
Dec 18, 2024Sell(S)4K$41.33$156K86K
Dec 18, 2024Option exercise(M)2K$2.90$6K88K
Dec 18, 2024Sell(S)2K$42.35$93K86K
Dec 18, 2024Option exercise(M)5K$2.90$15K91K
Dec 18, 2024Option exercise(M)4K$2.90$11K90K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 19, 2024Option exercise(M)58K—$0627K
Dec 18, 2024Option exercise(M)16K—$0686K
Dec 18, 2024Option exercise(M)2K—$0684K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001415889-24-029964) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML